Skip to main content

Table 1 Baseline demographic, clinical, and laboratory characteristics of the study patients according to tertiles of fibrinogen

From: The prognostic role of plasma fibrinogen in adult secondary hemophagocytic lymphohistiocytosis

 

Total (N = 293)

Tertile 1 (N = 99)

Tertile 2 (N = 97)

Tertile 3 (N = 97)

P

FIB, g/L

1.50 (1.02–2.18)

0.86 (0.70–1.03)

1.51 (1.38–1.72)

2.59 (2.18–3.33)

< 0.001

Male, n (%)

183 (62.5)

62 (62.6)

60 (61.9)

61 (62.9)

0.988

Age, years

53 (41–64)

51 (33–64)

56 (39–62)

55 (46–66)

0.118

ANC, \(\times \hspace{0.17em}\)109/L

1.32 (0.69–2.35)

1.04 (0.57–2.11)

1.36 (0.77–2.24)

1.55 (0.81–2.71)

0.057

HB, g/L

86 (71–100)

84 (77–95)

90 (73–107)

82 (68–97)

0.111

PLT,\(\times \hspace{0.17em}\)109/L

43 (24–72)

31 (18–52)

45 (25–80)

54 (32–97)

< 0.001

ALT, U/L

67.1 (36.3–149.1)

98.6 (50.6–235.4)

77.6 (32.4–143.2)

50.1 (28.4–82.3)

< 0.001

AST, U/L

91 (46.1–203.8)

178.5 (78.1–411.0)

90.2 (45.1–198.1)

61.0 (39.5–121.65)

< 0.001

LDH, U/L

676 (394.0–1308.5)

1004 (580.0–1793.0)

646 (354.5–1101.0)

540 (379.5–934.0)

< 0.001

TG, mmol/L

2.47 (1.71–3.70)

2.78 (1.77–4.04)

2.52 (1.89–3.67)

2.01 (1.58–3.18)

0.015

Ferritin, ug/L

4739 (1522–12,798)

8133 (2000–20,000)

3639 (1613–9558)

2841 (1494–7095)

< 0.001

sCD25, ng/L

33,480 (17,442–51,668)

40,042 (22,660–55,919)

26,920 (14,266–48,289)

32,939 (16,018–47,762)

0.024

β2-MG, mg/L

5.97 (4.41–8.53)

5.91 (4.19–8.53)

7.63 (4.85–9.28)

5.69 (3.88–8.04)

0.030

Fever, °C

39.5 (39.0–40.0)

39.6 (39.0–40.0)

39.4 (39.0–40.0)

39.3 (39.0–40.0)

0.143

Splenomegaly (%)

260 (88.7)

90 (90.9)

88 (90.7)

82 (84.5)

0.278

Lymphadenopathy (%)

152 (51.9)

45 (45.5)

52 (53.6)

55 (56.7)

0.265

Hemophagocytic (%)

260 (88.7)

88 (88.9)

85 (87.6)

87 (89.7)

0.900

HScore, points

234 (205–269)

255 (224–283)

235 (210–274)

219 (179–244)

< 0.001

EBV infection (%)

148 (50.5)

65 (65.7)

44 (45.4)

39 (40.2)

0.001

Etiology

0.120

 MHLH (%)

169 (57.7)

65 (65.7)

50 (51.5)

54 (55.7)

 

 Non-MHLH (%)

124 (42.3)

34 (34.3)

47 (48.5)

43 (44.3)

 

Treatment

0.960

 Chem ± HLH-94 (%)

167 (57.0)

58 (58.6)

53 (54.6)

56 (57.7)

 

 GC ± IVIG ± CsA ± VP16 (%)

112 (38.2)

36 (36.4)

40 (41.2)

36 (37.1)

 

 Support (%)

14 (4.8)

5 (5.1)

4 (4.1)

5 (5.2)

 
  1. Italics indicate statistical significance (P < 0.05)
  2. FIB fibrinogen, ANC absolute neutrophil count, HB hemoglobin, PLT platelet, ALT alanine transaminase, AST aspartate transaminase, LDH lactate dehydrogenase, ALB albumin, TG triglyceride, sCD25 soluble interleukin-2 receptor, β2-MG beta2-microglobulin, EBV Epstein-Barr virus, MHLH malignancy-associated haemophagocytic lymphohistiocytosis, Non-MHLH non-malignancy associated haemophagocytic lymphohistiocytosis, GC glucocorticoid, IVIg intravenous immunoglobulins, CsA cyclosporine, VP16 etoposide